News

News

23 Feb - Cell Lines & Media for Difficult to Culture Tumor Types

AMSBIO has introduced a new range of cancer cell line models and culture media for the most difficult to culture tumor types where no models may exist. Alex Sim, Managing Director at AMSBIO said, “Our new partnership with Cellaria Biosciences expands our existing portfolio by ...
READ MORE

23 Feb - Oxford Immunotec to Present at the Cowen and Company 37th Annual Health Care Conference

OXFORD, United Kingdom and MARLBOROUGH, Mass., February 22, 2017 (GLOBE NEWSWIRE) — Oxford Immunotec Global PLC (Nasdaq: OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced Dr. Peter Wrighton-Smith, Chief Executive Officer, ...
READ MORE

23 Feb - SRG 2017 Salary Survey now available

The latest figures, the deepest insights, the most comprehensive expertise Bringing you the science industry’s most comprehensive insight into remuneration, rewards and market trends, we’re delighted to present our latest Salary Survey in association with New Scientist. Based on responses from over 3,000 science professionals, ...
READ MORE

17 Feb - Reach Separations Turns 5!

February the 13th saw Reach Separations celebrate five years of laboratory occupation at Biocity Nottingham. Five years signifies a great start and our now established reputation for both speed and quality has meant that we have seen significant growth over the last 12 months, particularly ...
READ MORE

15 Feb - Oxford Immunotec Schedules Fourth Quarter and Full Year 2016 Earnings Release and Conference Call for February 28, 2017

OXFORD, United Kingdom and MARLBOROUGH, Mass., February 14, 2017 (GLOBE NEWSWIRE) — Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced that it plans to release fourth quarter ...
READ MORE

08 Feb - Contractor appointed for £13 million landmark Oxford scheme

The Oxford Science Park has awarded a £13 million design and build contract for Plot 12, a new state of the art office building, capable of housing laboratories, and with roof terrace, comprising 61,500 sq ft (5,713 sq m), to Barnwood Construction Ltd. Gloucestershire-based Barnwood ...
READ MORE

08 Feb - Cutting Edge Tools for Neuroscience Research

AMSBIO has published a new 25-page Neuroscience catalogue that details its extensive range of specific tools and reagents to enable researchers stay at the forefront of their field. Cellular models are key tools that open the door to numerous neuroscience applications including neurodegeneration, neurogensis and ...
READ MORE

02 Feb - Summit Therapeutics to Participate in February Investor Conferences

02 February 2017: Oxford, UK – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection, announces that company management will participate in three upcoming investor conferences taking place in New York ...
READ MORE